Natera, Inc. - Common Stock (NQ:NTRA)

Genetic testing company Natera (NASDAQ:NTRA) will be announcing earnings results this Thursday after the bell. Here’s what to expect. Natera beat analysts’ r...

Natera (NTRA) to report earnings tomorrow: here is what to expect

November 03, 2026

Performance

52-Week Range 11.9% below 52-week high

385.28

181.0052W Low 437.4152W High

1 Week 11.7% below 1-week high

376.381W Low 436.191W High

Natera, Inc. - Common Stock (NTRA) traded between $181.00 and $437.41 over the past 52 weeks and last traded at $385.28, 11.9% below its 52-week high. Over the past week it ranged between $376.38 and $436.19.

Past 12 Months

-9.2%

-9.5%

+40.0%

+86.3%

+68.4%

+94.4%

1W -$39.14

1M -$40.36

3M +$110.09

6M +$178.51

YTD +$156.44

1Y +$187.05

NTRA was +94.4% over the past year, +86.3% over six months, +68.4% year to date, -9.2% in the last week.

12 Months vs Market

NTRA

+94.4%

DIA

+12.4%

SPY

+12.4%

QQQ

+10.0%

IWM

+15.6%

Over the past 12 months NTRA returned +94.4% versus DIA (Dow) +12.4%, SPY (S&P 500) +12.4%, QQQ (Nasdaq 100) +10.0% and IWM (Russell 2000) +15.6%.

Volume & Liquidity 0.88× 3-mo avg

Today 1,427,266 3-mo avg 1.6M

2.4M

1.8M

1.6M

YTD

1.4M

NTRA most recently traded 1,427,266 shares against a 3-month average daily volume of 1.6M.

More News

Medicare Expands Coverage for Signatera™ MRD Test in Hepatocellular Carcinoma

November 03, 2026

Natera to Report its Third Quarter Results on November 5, 2026

October 29, 2026

Signatera™ Genome with Phased and Structural Variants Highlighted in ESMO Presidential Symposium, Supporting the Critical Role of MRD-Guided Treatment in Bladder Cancer

October 27, 2026

Natera Shares Real-World Analyses and Data at ASN Kidney Week 2026, Highlighting the Critical Need for Genetic Testing with Renasight™

October 26, 2026

Stanley Druckenmiller Has Bet Big on This 1 Healthcare Stock. Here's Why I Disagree. ↗

October 25, 2026

Via The Motley Fool

Why Natera (NTRA) Stock Is Up Today

October 19, 2026

ESMO 2026 Presentations Deepen the Evidence Base for Natera’s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology

October 18, 2026

Natera’s Signatera™ MRD Test Named to TIME’s List of the Best Inventions of 2026

October 15, 2026

Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer

October 13, 2026

Why Natera (NTRA) Stock Is Up Today

October 09, 2026

FDA Grants Breakthrough Device Designation for Natera’s Multi-Cancer Early Detection Assay

October 09, 2026

3 Market-Beating Stocks with Competitive Advantages

October 08, 2026

Natera Announces Randomized, Signatera™-Guided Interventional Study in Melanoma

October 07, 2026

New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists

October 06, 2026

October 06, 2026

Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (SERD) with Signatera™ MRD-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

October 05, 2026

2 Growth Stocks to Stash and 1 That Underwhelm

October 05, 2026

1 Unprofitable Stock to Target This Week and 2 We Question

September 30, 2026

Stocks making big moves yesterday: AutoZone, Natera, Shopify, Twilio, and Lennar

September 23, 2026

Why Is Natera (NTRA) Stock Soaring Today

September 22, 2026

Signatera™ Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer

September 22, 2026

Natera CEO Steven Chapman Sells 1,698 Shares for $545,000 ↗

September 18, 2026

Via The Motley Fool

Largest MRD Study in Lung Cancer Highlights Strong Prognostic Value for SignateraTM

September 18, 2026